Viking Therapeutics, BioNxt Solutions, and Bausch Health: Clinical Success Sparks Fresh Optimism

Viking Therapeutics: Moderate Quarterly Results

Viking Therapeutics is known for its weight-loss medications; its weight-loss injection, in particular, has recently drawn attention. The company has now released its results for the second quarter of 2026. The company reported a loss of USD 1.10 per share, which was less than the USD 1.23 loss analysts had anticipated. At the same time, spending on research and development projects increased. As of the quarter-end reporting date, the company had cash and cash equivalents totaling USD 502 million.

In the area of clinical trials, Viking Therapeutics confirmed that patient recruitment for the advanced Phase 3 trials of the drug VK2735, also known as the weight-loss injection, has been successfully completed.

The start of another late-stage trial is scheduled for the fourth quarter of the year, in which the drug will be tested in tablet form as an alternative. In addition, new trial data is expected during the third quarter to assess whether the dosing intervals can be extended to a schedule of two to four weeks. To broaden its research efforts in the field of obesity, the company has also initiated the first phase of testing for the compound VK3019.

During the same period, there was a change in management's stock holdings. On July 29, 2026, Chief Financial Officer Greg Zante sold exactly 21,217 shares of the company's common stock. The sale took place in several tranches at an average price of USD 33.47, corresponding to a total value of more than USD 710,000. However, this transaction was conducted solely to settle outstanding tax liabilities.

On the day before the transaction, the CFO had received 31,667 new shares of the company through a compensation program. The tax liabilities arising from this allocation were financed by the immediate partial sale. Following the completion of all transactions, the CFO continues to hold 212,204 shares of Viking Therapeutics in his personal portfolio.

BioNxt Solutions: Next Study Underway

With its semaglutide program, BioNxt Solutions is reaching the next stage of development for its innovative drug platform. The company is working on a sublingual, orally dissolving thin film (ODF) designed to deliver GLP-1 agonists such as semaglutide without the need for injections in the future. With this, BioNxt is targeting one of the most dynamic pharmaceutical markets of all. Analysts at Morgan Stanley expect the global market size for GLP-1 therapies to grow to approximately USD 190 billion by 2035. The company's strategy targets precisely where current therapies still have weaknesses, as a simple, needle-free application could significantly improve convenience, adherence, and acceptance. Following successful feasibility studies, the next phase of pharmaceutical development is now underway, involving formulation optimization, analytical testing, and preparation for further preclinical studies.

Rather than developing new active ingredients, BioNxt Solutions focuses on modern delivery systems for already established drugs with high market potential. The proprietary platform is designed to bypass the gastrointestinal tract and deliver active ingredients directly through the oral mucosa. This approach could offer decisive advantages, particularly for sensitive peptide active ingredients. At the same time, the technology opens up long-term prospects for additional GLP-1 active ingredients as well as numerous other indications.

However, the business model extends far beyond the semaglutide program. In addition to sublingual thin films, BioNxt is also developing transdermal patches, oral dosage forms, and a platform for targeted chemotherapies. The flagship of the pipeline is currently BNT23001, a cladribine thin film for the treatment of multiple sclerosis, which, following successful GMP production, is now awaiting bioequivalence testing. With the acquisition of the German company Vektor Pharma TF, BioNxt now has its own GMP-certified development and production capacities as well as comprehensive formulation expertise. A broad patent portfolio with protection extending through at least 2043 further strengthens the company's technological position.

At the same time, the company is pursuing licensing partnerships and expanding its international marketing strategy. If the bioavailability of the thin-film technology can be demonstrated, BioNxt could become an attractive partner for major pharmaceutical companies looking to enhance existing blockbuster drugs with modern dosage forms. The combination of scalable platform technology, extensive patent protection, and multiple development programs thus provides BioNxt with significant potential for the coming years.

Bausch Health: Annual Forecast Shattered

The pharmaceutical company Bausch Health, which develops, manufactures, and markets prescription drugs as well as products for ophthalmology, gastroenterology, dermatology, and neurology, also recently released its second-quarter results, showing increases in key financial metrics. Consolidated revenue totaled USD 2.85 billion, representing a 13% increase over the previous year. Excluding acquisitions and currency effects, revenue growth was 11%. The Salix, Bausch + Lomb, and Solta Medical business units were primarily responsible for this performance. The drug Xifaxan from the Salix division recorded a 26% increase in sales.

Earnings also developed positively. Net income reached USD 258 million, with unadjusted earnings per share of USD 0.68. Adjusted earnings were USD 1.26, a 40% increase compared to the same period last year, exceeding forecasts. Adjusted EBITDA grew by 28% to USD 1.075 billion.

In terms of liquidity, the Group generated operating cash flow of USD 517 million. According to CEO Thomas J. Appio, net debt was reduced to a level not seen since the last major debt restructuring in 2022. This reduction in liabilities is expected to give the company greater financial flexibility in the future for business expansion and new investments.

Based on the latest financial results for the past quarter, management has revised its targets for the full year 2026 upward. Bausch Health now expects higher figures for total revenue, adjusted EBITDA, and cash flow generated. The adjustment to the annual forecast is based on strong first-half results and sustained business performance in the company's core areas.

Viking Therapeutics is progressing through its clinical programs according to plan and, with more than USD 500 million in cash and cash equivalents, has a solid foundation for the next stages of development. BioNxt Solutions could tap into the multi-billion-dollar GLP-1 market with its needle-free semaglutide thin-film technology and establish itself as an attractive partner for the pharmaceutical industry. Bausch Health impresses with strong quarterly figures, an upwardly revised full-year forecast, and a noticeably improved balance sheet, all of which underscore its positive operational performance.